Osaic Holdings
SABS icon

Osaic Holdings’s SAB Biotherapeutics SABS Stock Holding History

Osaic Holdings’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.8K Buy
7,775
+2,751
+55% +$11K ﹤0.01% 5586
2025
Q4 		$18.8K Buy
5,024
+200
+4% +$658 ﹤0.01% 5922
2025
Q3 		$9.99K Sell
4,824
-113
-2% -$255 ﹤0.01% 6357
2025
Q2 		$8.64K Sell
4,937
-10
-0.2% -$17 ﹤0.01% 6235
2025
Q1 		$6.73K Sell
4,947
-100
-2% -$229 ﹤0.01% 6016
2024
Q4 		$19.1K Buy
5,047
+513
+11% +$1.69K ﹤0.01% 5379
2024
Q3 		$12.2K Hold
4,534
– – ﹤0.01% 5685
2024
Q2 		$14.1K Buy
4,534
+10
+0.2% +$37 ﹤0.01% 5567
2024
Q1 		$20.5K Sell
4,524
-113
-2% -$622 ﹤0.01% 5347
2023
Q4 		$31.9K Sell
4,637
-30
-0.6% -$252 ﹤0.01% 5198
2023
Q3 		$29.4K Buy
4,667
+2,777
+147% +$20.4K ﹤0.01% 5334
2023
Q2 		$15.7K Sell
1,890
-20
-1% -$164 ﹤0.01% 5717
2023
Q1 		$8.4K Hold
1,910
– – ﹤0.01% 6071
2022
Q4 		$11.3K Buy
1,910
+1,689
+764% +$15.4K ﹤0.01% 5874
2022
Q3 		$2K Hold
221
– – ﹤0.01% 6822
2022
Q2 		$3K Buy
221
+88
+66% +$1.85K ﹤0.01% 6755
2022
Q1 		$5K Sell
133
-68
-34% -$3.14K ﹤0.01% 6499
2021
Q4 		$16K Buy
+201
New +$18.9K ﹤0.01% 5954

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings's SABS Position: Q1 2026 in Review

Osaic Holdings increased its SAB Biotherapeutics (SABS) stake by 55% in Q1 2026, buying an estimated $11K and bringing the position to 7,775 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5586.

Osaic Holdings first reported a position in SABS in Q4 2021 and has held it in 18 quarters since. The position peaked at $31.9K in Q4 2023. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Osaic Holdings held 7,775 shares of SAB Biotherapeutics worth $29.8K as of Q1 2026.
  • Osaic Holdings bought 2,751 SAB Biotherapeutics shares in Q1 2026, an estimated $11K.
  • SAB Biotherapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #5586 holding.
  • Osaic Holdings first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 18 quarters since.
  • Osaic Holdings's SAB Biotherapeutics position peaked at $31.9K in Q4 2023.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.